Blog
RSS FeedPosted by Michael Wonder on 19 Aug 2023
Quebec becomes the first province to reimburse Minjuvi (tafasitamab) in combination with lenalidomide for patients with diffuse large B-cell lymphoma
17 August 2023 - This is the first public listing since Minjuvi was approved with conditions by Health Canada in ...
Posted by Michael Wonder on 03 Aug 2023
Jazz Pharmaceuticals enters into letter of intent with the pan-Canadian Pharmaceutical Alliance for Rylaze, helping address the unmet need of acute lymphoblastic leukaemia and lymphoblastic lymphoma patients across Canada
2 August 2023 - Jazz Pharmaceuticals today announced that the Company has entered into a letter of intent with the pan-Canadian ...
Posted by Michael Wonder on 11 Jul 2023
Pluvicto receives positive recommendations from CADTH and INESSS for progressive PSMA positive metastatic castration-resistant prostate cancer
10 July 2023 - Health technology assessment agencies reinforce the therapeutic value of Pluvicto and need for new approaches to treat ...
Posted by Michael Wonder on 25 May 2023
FORUS Therapeutics and the Pan-Canadian Pharmaceutical Alliance complete negotiations for Xpovio (selinexor)
24 May 2023 - The pCPA agreement will support the public listings and reimbursement of Xpovio. ...
Posted by Michael Wonder on 20 Apr 2023
Rybrevant (amivantamab) receives positive CADTH reimbursement recommendation for the treatment of adult patients with non-small cell lung cancer with activating EGFR exon 20 insertion mutations
6 April 2023 - This CADTH recommendation is a step towards public access to Rybrevant as a targeted therapy for ...
Posted by Michael Wonder on 09 Feb 2023
Quebec becomes first province to cover Brukinsa (zanubrutinib) for the treatment of Waldenström's macroglobulinemia
6 February 2023 - First and only Bruton's tyrosine kinase inhibitor to be granted provincial formulary approval. ...
Posted by Michael Wonder on 07 Dec 2022
Tukysa (tucatinib) reimbursed in British Columbia for the treatment of patients with advanced or metastatic HER2 positive breast cancer
6 December 2022 - BC is the third province to add Tukysa to its provincial dormulary. ...
Posted by Michael Wonder on 01 Nov 2022
Verzenio (abemaciclib) receives positive reimbursement recommendation from CADTH for early breast cancer
1 November 2022 - Lilly Canada announced today that CADTH has issued their final reimbursement recommendation for Verzenio (abemaciclib) in ...
Posted by Michael Wonder on 25 Oct 2022
A perspective on life cycle health technology assessment and real world evidence for precision oncology in Canada
25 October 2022 - Health technology assessment can be used to make healthcare systems more equitable and efficient. Advances in precision ...
Posted by Michael Wonder on 11 Oct 2022
Trying to survive: To access lifesaving drugs, young cancer patients face huge hurdles
10 October 2022 - Four years ago, Ontarian Rebecca Grundy got a nightmare diagnosis that sent her into a blind ...
Posted by Michael Wonder on 05 Oct 2022
Tecentriq (atezolizumab) receives CADTH reimbursement recommendations for the adjuvant treatment of early-stage non-small-cell lung cancer and the treatment of extensive stage small cell lung cancer
5 October 2022 - The CADTH recommendations are a step towards public funding of this treatment option for some patients with ...
Posted by Michael Wonder on 08 Aug 2022
Funding for lifesaving drug denied by B.C. health authority as couple struggles to fund their portion
7 August 2022 - Entrectinib, a targeted drug that had shown positive results in tumours that had the same gene expression, ...
Posted by Michael Wonder on 21 Apr 2022
Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...
Posted by Michael Wonder on 24 Feb 2022
AbbVie announces provincial reimbursement for Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia in Alberta, Saskatchewan, British Columbia and Manitoba
24 February 2022 - AbbVie announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta (venetoclax) in combination ...
Posted by Michael Wonder on 11 Feb 2022
AbbVie announces first provincial reimbursements for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients
10 February 2022 - Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance, Quebec, Saskatchewan, and ...